Transition metals and mitochondrial metabolism in the heart

Journal of Molecular and Cellular Cardiology

Volumn 55, Issue 1, 2013, Pages 50-57

  Rines, Amy K ^a   Ardehali, Hossein ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Copper; Heart; Iron; Manganese; Mitochondria; Transition metals

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; ANTIOXIDANT; CD71 ANTIGEN; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; DEFEROXAMINE; DOXORUBICIN; FERROPORTIN; FRATAXIN; HEME OXYGENASE 1; HFE PROTEIN; IRON; IRON CHELATING AGENT; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; MANGANESE; MANGANESE SUPEROXIDE DISMUTASE; RAZOXANE; REACTIVE OXYGEN METABOLITE; TRANSFERRIN; TRANSITION ELEMENT;

ANTIOXIDANT ACTIVITY; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DAMAGE; CELL ENERGY; CELL ORGANELLE; COATED PIT; COPPER METABOLISM; DISEASE ASSOCIATION; ENZYME MECHANISM; FRIEDREICH ATAXIA; FXN GENE; GENE; GENE MUTATION; HEART FUNCTION; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW;

ANIMALS; COPPER; HEART; HUMANS; IRON; MANGANESE; METALS; MITOCHONDRIA, HEART; MYOCARDIUM; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 84872679855     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.05.014     Document Type: Review

References (101)

1. Nelson N. Metal ion transporters and homeostasis. EMBO J 1999, 18:4361-4371.
2. Aisen P., Enns C., Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol 2001, 33:940-959.
3. Wardman P., Candeias L.P. Fenton chemistry: an introduction. Radiat Res 1996, 145:523-531.
4. Thannickal V.J., Fanburg B.L. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000, 279:L1005-L1028.
5. Wang J., Pantopoulos K. Regulation of cellular iron metabolism. Biochem J 2011, 434:365-381.
6. Hentze M.W., Muckenthaler M.U., Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004, 117:285-297.
7. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093.
8. Rouault T.A. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol 2006, 2:406-414.
9. Pantopoulos K. Iron metabolism and the IRE/IRP regulatory system: an update. Ann N Y Acad Sci 2004, 1012:1-13.
10. Huang M.L., Lane D.J., Richardson D.R. Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease. Antioxid Redox Signal 2011, 15:3003-3019.
11. Richardson D.R., Lane D.J., Becker E.M., Huang M.L., Whitnall M., Suryo Rahmanto Y., et al. Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc Natl Acad Sci U S A 2010, 107:10775-10782.
12. Chen W., Paradkar P.N., Li L., Pierce E.L., Langer N.B., Takahashi-Makise N., et al. Abcb10 physically interacts with mitoferrin-1 (Slc25a37) to enhance its stability and function in the erythroid mitochondria. Proc Natl Acad Sci U S A 2009, 106:16263-16268.
13. Ichikawa Y., Bayeva M., Ghanefar M., Potini V., Sun L., Mutharasan R.K., et al. Disruption of ATP-binding cassette B8 in mice leads to cardiomyopathy through a decrease in mitochondrial iron export. Proc Natl Acad Sci U S A 2012, 109:4152-4157.
14. Bekri S., Kispal G., Lange H., Fitzsimons E., Tolmie J., Lill R., et al. Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. Blood 2000, 96:3256-3264.
15. Cavadini P., Biasiotto G., Poli M., Levi S., Verardi R., Zanella I., et al. RNA silencing of the mitochondrial ABCB7 transporter in HeLa cells causes an iron-deficient phenotype with mitochondrial iron overload. Blood 2007, 109:3552-3559.
16. Huss J.M., Kelly D.P. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 2005, 115:547-555.
17. Atamna H., Walter P.B., Ames B.N. The role of heme and iron-sulfur clusters in mitochondrial biogenesis, maintenance, and decay with age. Arch Biochem Biophys 2002, 397:345-353.
18. Chen Q., Vazquez E.J., Moghaddas S., Hoppel C.L., Lesnefsky E.J. Production of reactive oxygen species by mitochondria: central role of complex III. J Biol Chem 2003, 278:36027-36031.
19. van Veldhuisen D.J., Anker S.D., Ponikowski P., Macdougall I.C. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 2011, 8:485-493.
20. Gujja P., Rosing D.R., Tripodi D.J., Shizukuda Y. Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol 2010, 56:1001-1012.
21. Payne R.M. The heart in Friedreich's ataxia: basic findings and clinical implications. Prog Pediatr Cardiol 2011, 31:103-109.
22. Tay E.L., Peset A., Papaphylactou M., Inuzuka R., Alonso-Gonzalez R., Giannakoulas G., et al. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol 2011, 151:307-312.
23. Jankowska E.A., Rozentryt P., Witkowska A., Nowak J., Hartmann O., Ponikowska B., et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail 2011, 17:899-906.
24. Mavrogeni S., Gotsis E., Verganelakis D., Berdousis E., Dritsas A., Kolovou G., et al. Effect of iron overload on exercise capacity in thalassemic patients with heart failure. Int J Cardiovasc Imaging 2009, 25:777-783.
25. Ramakrishnan U., Kuklina E., Stein A.D. Iron stores and cardiovascular disease risk factors in women of reproductive age in the United States. Am J Clin Nutr 2002, 76:1256-1260.
26. Fleming R.E., Ponka P. Iron overload in human disease. N Engl J Med 2012, 366:348-359.
27. Huang J., Jones D., Luo B., Sanderson M., Soto J., Abel E.D., et al. Iron overload and diabetes risk: a shift from glucose to fatty acid oxidation and increased hepatic glucose production in a mouse model of hereditary hemochromatosis. Diabetes 2011, 60:80-87.
28. Bartfay W.J., Butany J., Lehotay D.C., Sole M.J., Hou D., Bartfay E., et al. A biochemical, histochemical, and electron microscopic study on the effects of iron-loading on the hearts of mice. Cardiovasc Pathol 1999, 8:305-314.
29. Gao X., Qian M., Campian J.L., Marshall J., Zhou Z., Roberts A.M., et al. Mitochondrial dysfunction may explain the cardiomyopathy of chronic iron overload. Free Radic Biol Med 2010, 49:401-407.
30. Asín J., Pérez-Martos A., Fernández-Silva P., Montoya J., Andreu A.L. Iron(II) induces changes in the conformation of mammalian mitochondrial DNA resulting in a reduction of its transcriptional rate. FEBS Lett 2000, 480:161-164.
31. Kim M., Kim J., Cheon C.I., Cho D.H., Park J.H., Kim K.I., et al. Increased expression of the F(1)F(o) ATP synthase in response to iron in heart mitochondria. BMB Rep 2008, 41:153-157.
32. Link G., Saada A., Pinson A., Konijn A.M., Hershko C. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. J Lab Clin Med 1998, 131:466-474.
33. Link G., Konijn A.M., Hershko C. Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells. J Lab Clin Med 1999, 133:179-188.
34. Glickstein H., El R.B., Link G., Breuer W., Konijn A.M., Hershko C., et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 2006, 108:3195-3203.
35. Tanne Z., Coleman R., Nahir M., Shomrat D., Finberg J.P., Youdim M.B. Ultrastructural and cytochemical changes in the heart of iron-deficient rats. Biochem Pharmacol 1994, 47:1759-1766.
36. Dong F., Zhang X., Culver B., Chew H.G., Kelley R.O., Ren J. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond) 2005, 109:277-286.
37. Kim M., Song E. Effects of ATP and ADP on iron uptake in rat heart mitochondria. Anim Cells Syst 2010, 14:245-252.
38. Sanz J. Evolving diagnostic and prognostic imaging of the various cardiomyopathies. Ann N Y Acad Sci 2012, 1254:123-130.
39. Carpenter J.P., He T., Kirk P., Roughton M., Anderson L.J., de Noronha S.V., et al. On T22* magnetic resonance and cardiac iron. Circulation 2011, 123:1519-1528.
40. Campuzano V., Montermini L., Moltò M.D., Pianese L., Cossée M., Cavalcanti F., et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996, 271:1423-1427.
41. Rötig A., de Lonlay P., Chretien D., Foury F., Koenig M., Sidi D., et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 1997, 17:215-217.
42. Sanchez-Casis G., Cote M., Barbeau A. Pathology of the heart in Friedreich's ataxia: review of the literature and report of one case. Can J Neurol Sci 1976, 3:349-354.
43. Pandolfo M. Frataxin deficiency and mitochondrial dysfunction. Mitochondrion 2002, 2:87-93.
44. Puccio H., Simon D., Cossée M., Criqui-Filipe P., Tiziano F., Melki J., et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 2001, 27:181-186.
45. Richardson D.R., Huang M.L., Whitnall M., Becker E.M., Ponka P., Suryo Rahmanto Y. The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia. J Mol Med (Berl) 2010, 88:323-329.
46. Huang M.L., Becker E.M., Whitnall M., Suryo Rahmanto Y., Ponka P., Richardson D.R. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc Natl Acad Sci U S A 2009, 106:16381-16386.
47. Babcock M., de Silva D., Oaks R., Davis-Kaplan S., Jiralerspong S., Montermini L., et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 1997, 276:1709-1712.
48. Wilson R.B., Roof D.M. Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue. Nat Genet 1997, 16:352-357.
49. Zhang Y., Lyver E.R., Knight S.A., Pain D., Lesuisse E., Dancis A. Mrs3p, Mrs4p, and frataxin provide iron for Fe-S cluster synthesis in mitochondria. J Biol Chem 2006, 281:22493-22502.
50. Tsai C.L., Barondeau D.P. Human frataxin is an allosteric switch that activates the Fe-S cluster biosynthetic complex. Biochemistry 2010, 49:9132-9139.
51. Bulteau A.L., O'Neill H.A., Kennedy M.C., Ikeda-Saito M., Isaya G., Szweda L.I. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 2004, 305:242-245.
52. Schmucker S., Martelli A., Colin F., Page A., Wattenhofer-Donzé M., Reutenauer L., et al. Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/NFS1/ISD11 iron-sulfur assembly complex. PLoS One 2011, 6:e16199.
53. Yoon T., Cowan J.A. Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis. J Biol Chem 2004, 279:25943-25946.
54. Schoenfeld R.A., Napoli E., Wong A., Zhan S., Reutenauer L., Morin D., et al. Frataxin deficiency alters heme pathway transcripts and decreases mitochondrial heme metabolites in mammalian cells. Hum Mol Genet 2005, 14:3787-3799.
55. Lodi R., Cooper J.M., Bradley J.L., Manners D., Styles P., Taylor D.J., et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci U S A 1999, 96:11492-11495.
56. Lodi R., Rajagopalan B., Blamire A.M., Cooper J.M., Davies C.H., Bradley J.L., et al. Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study. Cardiovasc Res 2001, 52:111-119.
57. Ristow M., Pfister M.F., Yee A.J., Schubert M., Michael L., Zhang C.Y., et al. Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. Proc Natl Acad Sci U S A 2000, 97:12239-12243.
58. Vyas P.M., Tomamichel W.J., Pride P.M., Babbey C.M., Wang Q., Mercier J., et al. A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model. Hum Mol Genet 2012, 21:1230-1247.
59. Schulz T.J., Westermann D., Isken F., Voigt A., Laube B., Thierbach R., et al. Activation of mitochondrial energy metabolism protects against cardiac failure. Aging (Albany NY) 2010, 2:843-853.
60. Whitnall M., Suryo Rahmanto Y., Sutak R., Xu X., Becker E.M., Mikhael M.R., et al. The MCK mouse heart model of Friedreich's ataxia: alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proc Natl Acad Sci U S A 2008, 105:9757-9762.
61. Wong A., Yang J., Cavadini P., Gellera C., Lonnerdal B., Taroni F., et al. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet 1999, 8:425-430.
62. Richardson D.R. Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?. Expert Opin Investig Drugs 2003, 12:235-245.
63. Lodi R., Hart P.E., Rajagopalan B., Taylor D.J., Crilley J.G., Bradley J.L., et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol 2001, 49:590-596.
64. Hart P.E., Lodi R., Rajagopalan B., Bradley J.L., Crilley J.G., Turner C., et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 2005, 62:621-626.
65. Jauslin M.L., Meier T., Smith R.A., Murphy M.P. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J 2003, 17:1972-1974.
66. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998, 339:900-905.
67. Hasinoff B.B., Schnabl K.L., Marusak R.A., Patel D., Huebner E. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol 2003, 3:89-99.
68. Miranda C.J., Makui H., Soares R.J., Bilodeau M., Mui J., Vali H., et al. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood 2003, 102:2574-2580.
69. Hellmann K. Preventing the cardiotoxicity of anthracyclines by dexrazoxane. BMJ 1999, 319:1085-1086.
70. Lebrecht D., Geist A., Ketelsen U.P., Haberstroh J., Setzer B., Walker U.A. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol 2007, 151:771-778.
71. Thompson K.L., Rosenzweig B.A., Zhang J., Knapton A.D., Honchel R., Lipshultz S.E., et al. Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. Cancer Chemother Pharmacol 2010, 66:303-314.
72. Spagnuolo R.D., Recalcati S., Tacchini L., Cairo G. Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity. Br J Pharmacol 2011, 163:299-312.
73. Nose Y., Kim B.E., Thiele D.J. Ctr1 drives intestinal copper absorption and is essential for growth, iron metabolism, and neonatal cardiac function. Cell Metab 2006, 4:235-244.
74. Kim B.E., Turski M.L., Nose Y., Casad M., Rockman H.A., Thiele D.J. Cardiac copper deficiency activates a systemic signaling mechanism that communicates with the copper acquisition and storage organs. Cell Metab 2010, 11:353-363.
75. Cherukuri S., Potla R., Sarkar J., Nurko S., Harris Z.L., Fox P.L. Unexpected role of ceruloplasmin in intestinal iron absorption. Cell Metab 2005, 2:309-319.
76. Yoshida K., Furihata K., Takeda S., Nakamura A., Yamamoto K., Morita H., et al. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 1995, 9:267-272.
77. Kim B.E., Nevitt T., Thiele D.J. Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol 2008, 4:176-185.
78. Stiburek L., Vesela K., Hansikova H., Hulkova H., Zeman J. Loss of function of Sco1 and its interaction with cytochrome c oxidase. Am J Physiol Cell Physiol 2009, 296:C1218-C1226.
79. Liao Z., Medeiros D.M., McCune S.A., Prochaska L.J. Cardiac levels of fibronectin, laminin, isomyosins, and cytochrome c oxidase of weanling rats are more vulnerable to copper deficiency than those of postweanling rats. J Nutr Biochem 1995, 6:385-391.
80. Nath R. Copper deficiency and heart disease: molecular basis, recent advances and current concepts. Int J Biochem Cell Biol 1997, 29:1245-1254.
81. Medeiros D.M., Jiang Y., Klaahsen D., Lin D. Mitochondrial and sarcoplasmic protein changes in hearts from copper-deficient rats: up-regulation of PGC-1alpha transcript and protein as a cause for mitochondrial biogenesis in copper deficiency. J Nutr Biochem 2009, 20:823-830.
82. Zeng H., Saari J.T., Johnson W.T. Copper deficiency decreases complex IV but not complex I, II, III, or V in the mitochondrial respiratory chain in rat heart. J Nutr 2007, 137:14-18.
83. Johnson W.T., Newman S.M. Hearts in adult offspring of copper-deficient dams exhibit decreased cytochrome c oxidase activity, increased mitochondrial hydrogen peroxide generation and enhanced formation of intracellular residual bodies. J Nutr Biochem 2007, 18:97-104.
84. Li Y., Wang L., Schuschke D.A., Zhou Z., Saari J.T., Kang Y.J. Marginal dietary copper restriction induces cardiomyopathy in rats. J Nutr 2005, 135:2130-2136.
85. Chen X., Jennings D.B., Medeiros D.M. Impaired cardiac mitochondrial membrane potential and respiration in copper-deficient rats. J Bioenerg Biomembr 2002, 34:397-406.
86. Mao S., Medeiros D.M., Wildman R.E. Cardiac hypertrophy in copper-deficient rats is owing to increased mitochondria. Biol Trace Elem Res 1998, 64:175-184.
87. Johnson W.T., Johnson L.K. Copper deficiency inhibits Ca2+-induced swelling in rat cardiac mitochondria. J Nutr Biochem 2009, 20:248-253.
88. Rossi L., Lippe G., Marchese E., De Martino A., Mavelli I., Rotilio G., et al. Decrease of cytochrome c oxidase protein in heart mitochondria of copper-deficient rats. Biometals 1998, 11:207-212.
89. Elsherif L., Wang L., Saari J.T., Kang Y.J. Regression of dietary copper restriction-induced cardiomyopathy by copper repletion in mice. J Nutr 2004, 134:855-860.
90. Zuo X., Xie H., Dong D., Jiang N., Zhu H., Kang Y.J. Cytochrome c oxidase is essential for copper-induced regression of cardiomyocyte hypertrophy. Cardiovasc Toxicol 2010, 10:208-215.
91. Jüllig M., Chen X., Hickey A.J., Crossman D.J., Xu A., Wang Y., et al. Reversal of diabetes-evoked changes in mitochondrial protein expression of cardiac left ventricle by treatment with a copper(II)-selective chelator. Proteomics Clin Appl 2007, 1:387-399.
92. Aschner M., Erikson K.M., Herrero Hernández E., Hernández E.H., Tjalkens R. Manganese and its role in Parkinson's disease: from transport to neuropathology. Neuromolecular Med 2009, 11:252-266.
93. Gunter T.E., Gerstner B., Lester T., Wojtovich A.P., Malecki J., Swarts S.G., et al. An analysis of the effects of Mn2+ on oxidative phosphorylation in liver, brain, and heart mitochondria using state 3 oxidation rate assays. Toxicol Appl Pharmacol 2010, 249:65-75.
94. Miller K.B., Newman S.M., Caton J.S., Finley J.W. Manganese alters mitochondrial integrity in the hearts of swine marginally deficient in magnesium. Biofactors 2004, 20:85-96.
95. Miller K.B., Caton J.S., Finley J.W. Manganese depresses rat heart muscle respiration. Biofactors 2006, 28:33-46.
96. Au C., Benedetto A., Aschner M. Manganese transport in eukaryotes: the role of DMT1. Neurotoxicology 2008, 29:569-576.
97. Wenzel P., Schuhmacher S., Kienhöfer J., Müller J., Hortmann M., Oelze M., et al. Manganese superoxide dismutase and aldehyde dehydrogenase deficiency increase mitochondrial oxidative stress and aggravate age-dependent vascular dysfunction. Cardiovasc Res 2008, 80:280-289.
98. Lijnen P.J., van Pelt J.F., Fagard R.H. Downregulation of manganese superoxide dismutase by angiotensin II in cardiac fibroblasts of rats: association with oxidative stress in myocardium. Am J Hypertens 2010, 23:1128-1135.
99. Van Remmen H., Williams M.D., Guo Z., Estlack L., Yang H., Carlson E.J., et al. Knockout mice heterozygous for Sod2 show alterations in cardiac mitochondrial function and apoptosis. Am J Physiol Heart Circ Physiol 2001, 281:H1422-H1432.
100. Yen H.C., Oberley T.D., Gairola C.G., Szweda L.I., St.Clair D.K. Manganese superoxide dismutase protects mitochondrial complex I against adriamycin-induced cardiomyopathy in transgenic mice. Arch Biochem Biophys 1999, 362:59-66.
101. Shen X., Zheng S., Metreveli N.S., Epstein P.N. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006, 55:798-805.